These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15119925)

  • 1. Ribavirin may be an important factor in IFN-induced neuropsychiatric effects.
    Asnis GM; De La Garza R; Miller AH; Raison CL
    J Clin Psychiatry; 2004 Apr; 65(4):581; author reply 581-2. PubMed ID: 15119925
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of chronic hepatitis C: side effects, tolerability and quality of life].
    Gournay J; Richou C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B60-75. PubMed ID: 12180310
    [No Abstract]   [Full Text] [Related]  

  • 4. [Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 1999 May; 124(20):636-42. PubMed ID: 10370387
    [No Abstract]   [Full Text] [Related]  

  • 5. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 6. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
    Adinolfi LE; Durante Mangoni E; Andreana A
    Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of chronic hepatitis C].
    Bell H; Dalgard O; Bjøro K; Hellum KB; Myrvang B
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):926-8. PubMed ID: 12082838
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.
    Bhatti A; McGarrity TJ; Gabbay R
    Am J Gastroenterol; 2001 Feb; 96(2):604-5. PubMed ID: 11232722
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dysacusia associated with pegylated-interferon and ribavirin combination therapy during chronic hepatitis C treatment: a report of two cases].
    Jia YH; Gao SJ; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):67-8. PubMed ID: 22489302
    [No Abstract]   [Full Text] [Related]  

  • 10. [New therapeutic possibilities in chronic hepatitis C].
    Criblez DH
    Praxis (Bern 1994); 2000 Mar; 89(11):450-3. PubMed ID: 10758732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion.
    Hong BA; North CS; Pollio DE; Abbacchi A; Debold C; Adewuyi SA; Lisker-Melman M
    J Clin Psychol Med Settings; 2011 Mar; 18(1):99-107. PubMed ID: 21336614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon for hepatitis C patients with psychiatric disorders.
    Rifai MA; Bozorg B; Rosenstein DL
    Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
    [No Abstract]   [Full Text] [Related]  

  • 14. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
    Kasahara A
    J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
    [No Abstract]   [Full Text] [Related]  

  • 15. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z; Delić D; Marić NP; Vuković O; Jašović-Gašić M
    Psychiatr Danub; 2011 Dec; 23(4):370-7. PubMed ID: 22075738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Enjoji M; Dainichi T; Gondo H; Urabe K
    Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects of therapy for chronic hepatitis C.
    Russo MW; Fried MW
    Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
    [No Abstract]   [Full Text] [Related]  

  • 19. The management of side-effects during therapy for hepatitis C.
    Aspinall RJ; Pockros PJ
    Aliment Pharmacol Ther; 2004 Nov; 20(9):917-29. PubMed ID: 15521838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.